Form 4: Tharimmune CEO Randy Milby Granted Stock Options
SEC Form 4
Tharimmune, Inc. CEO Randy Milby was granted options to purchase 57,707 shares of common stock on August 9, 2024.
Summary
- Randy Milby, CEO of Tharimmune, Inc., was granted options to purchase 57,707 shares of the company's common stock on August 9, 2024.
- The options were granted pursuant to the company's 2023 Omnibus Equity Incentive Plan.
- The exercise price of the options is $2.925.
- The options vest in 12 equal monthly installments, beginning on the date of grant.
- The options expire on August 9, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to executive compensation, and does not contain information that would significantly impact sentiment positively or negatively.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are common in the pharmaceutical industry to incentivize performance and align executive interests with shareholder value.
- Comparable companies in the biotechnology sector often use similar equity-based compensation plans to attract and retain top talent.
Stakeholder Impact
- The grant of stock options could potentially incentivize the CEO to improve company performance, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of the earliest transaction and grant date of the options. |
| 08/09/2034 | Expiration date of the options. |
| 08/12/2024 | Date of signature of the Form 4. |
Keywords
stock options, Tharimmune, CEO, Randy Milby, equity incentive plan, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.